The reiteration of an Outperform rating by Wedbush analyst Robert Driscoll indicates a positive outlook for Zentalis Pharma. The maintained $38 price target suggests that the stock is expected to perform well in the short term. This news is highly relevant and important for investors in ZNTL, and the confidence in the analysis is high due to the analyst's expertise.